www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2724

Title: Minimal clinically important difference in plain films in RA: Group discussions, conclusions, and recommendations
Authors: VAN DER HEIJDE, Desiree
Lassere, M
Edmonds, J
Kirwan, J
Strand, V
Boers, M
Issue Date: 2001
Publisher: J RHEUMATOL PUBL CO
Citation: JOURNAL OF RHEUMATOLOGY, 28(4). p. 914-917
Abstract: Analysis of progression of structural damage on an individual patient level in randomized controlled trials provides extra information in addition to the analysis on a group level. A cutoff level is required to define which patients show progression and which patients do not. The objective of the mimimal clinically important difference (MCID) module for plain films was to elaborate the various concepts to determine a MCID for plain films, and if possible, to define a MCID for specific scoring methods. The module comprised preconference reading material, a plenary session, small group discussions, and a plenary report of the group sessions. combined with interactive voting. The following conclusions and recommendations were made: the smallest detectable difference (SDD) beyond measurement error is a good starting point to define MCID; SDD is study-specific: SDD should be reported For all radiographic endpoints used in a trial as a quality control; the expert panel approach is a reasonable method to define MCID. but defined in this way MCID may be smaller than current SDD: more research is needed to validate expert panel based MCID in different datasets and with different experts: a predictive, data driven MCID is the ultimate goal, but is not yet available; the SDD can be used as a proxy for MCID until a data driven MCID is available: analysis at the group level (comparison of means or medians) should remain primary in studies that include progression of joint damage as outcome measure, the proportion of patients showing more progression than the SDD is a secondary outcome measure.
Notes: Univ Hosp Maastricht, Div Rheumatol, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands. Limburg Univ Ctr, Diepenbeek, Belgium. St George Hosp, Dept Rheumatol, Sydney, NSW, Australia. Univ Bristol, Bristol Royal Infirm, Div Med, Rheumatol Unit, Bristol, Avon, England. Stanford Univ, Div Immunol, San Francisco, CA USA. VU Univ Hosp, Dept Clin Epidemiol, Amsterdam, Netherlands.van der Heijde, D, Univ Hosp Maastricht, Div Rheumatol, Dept Internal Med, POB 5800, NL-6202 AZ Maastricht, Netherlands.
URI: http://hdl.handle.net/1942/2724
Link to publication: http://jrheum.com/abstracts/abstracts01/914.html
ISI #: 000167808600044
ISSN: 0315-162X
Category: A1
Type: Journal Contribution
Validation: ecoom, 2002
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.